Optimi is a commercial-stage pharmaceutical company manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. $OPTH
Canada
Joined April 2021
- Tweets865
- Following423
- Followers927
- Likes994
Pinned Tweet
👀🍄✈️ @MindMedicineAU
Currently in Canada we're growing the mushrooms, we're extracting the psilocybin, and shipping it across the world, but our physicians can't prescribe it. This makes no sense at all!
Please sign my petition supporting Thomas' Bill: thomasbill.ca/petition
Optimi retweeted
“There is something in common with what we're seeing about the impact of these different mechanisms where we are seeing benefit in these studies, and they do all have some change in perception.”
Carole Ho, Executive Vice President and President, Eli Lilly and Lilly Neuroscience, speaking at The Psychedelic Healthcare Forum.
When discussing the role of the subjective experience, or ‘trip’, in psychedelic therapies.
Optimi retweeted
Researchers are optimistic about psychedelic drugs as potential treatments for depression and mood disorders, despite pushback having stalled the field
go.nature.com/4iH8B9o
Optimi retweeted
Two years ago the FDA rejected the first psychedelic therapy for PTSD. Today the US government is openly asking how it can get these treatments to millions of veterans as quickly as possible.
That is a remarkable shift, and in my view it is not mainly about politics. It is about the fact that conventional psychiatry has very little to offer people with severe PTSD or treatment-resistant depression. Many veterans did not wait for Washington. They travelled to Mexico, got treated and came back with stories that were impossible to ignore.
The brain is the last great frontier in medicine. Psychedelics are one of the first tools that actually change how it works, rather than just managing symptoms.
Article in the comments.
Optimi Health CEO and Co-Founder Dane Stevens comments on the establishment of Optimi Australia, a new wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across the country. For details: bit.ly/4jHuV3Q $OPTH
Optimi Health announced the establishment of Optimi Australia Pty Ltd, a wholly owned subsidiary responsible for distribution and business development in Australia, and the appointment of Adrian Jones as Director of Australian Operations. bit.ly/4jHuV3Q $OPTH
Optimi retweeted
Since President Trump's psychedelics-focused Executive Order in April, a slew of federal agencies and departments have engaged in related activities: from funding psychedelic research through to public hearings and requests for information.
Optimi retweeted
New episode: Peaking director Jordan Kronick on taking cameras into the dosing room across six psychedelics, the 2004 doc that helped reopen MDMA research, and psychedelics for brain injury in pro sports.
bit.ly/pt662-peaking
$OPTH CEO Dane Stevens comments on the completion of the Company's latest MDMA finished drug product batch, expected to supply the proposed Phase 3 PTSD trial in Canada, a planned 2026 export to Australia, & a previously announced trial in Israel with MAPS. bit.ly/4ie9Xap
Optimi retweeted
Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:
• Early Notes from The Psychedelic Healthcare Forum
• FDA Floats an Ibogaine Trial Design, Asks Field for Input
• Compass Talks Pricing, Label and a Slow Launch
• New Mexico Nears Medical Psilocybin Launch
• Six More Potential Psychedelic Brand Names
Listen on our website or on your favourite podcast app: psychedelicalpha.com/news/po…
Optimi retweeted
As psychedelic treatments approach potential FDA approval, psychiatrists need to be ready for patients’ questions.
To help prepare them, Johns Hopkins, Yale, NYU, and Columbia developed a standardized psychedelic medicine curriculum for psychiatry trainees. The first multi-site evaluation of the course was just published in Academic Psychiatry.
After the course:
💡 Confidence counseling patients about clinical research and legal care nearly doubled
🔬 Understanding of the limitations of current evidence rose sharply
📈 Knowledge quiz scores improved
⚖️ Trainees gained a more balanced, critically informed view of the evidence, without inflated enthusiasm for the field
We’re continuing to develop educational and training programs for professionals across a range of fields, so stay tuned!
doi.org/10.1007/s40596-026-0…
Optimi retweeted
See our new paper on Psilocybin for Anhedonia in Unipolar and Bipolar Depression
sciencedirect.com/science/ar…
Progress starts long before a treatment reaches a patient.
It takes careful preparation, consistent processes, and people committed to getting the details right. That work is central to our approach at Optimi.
#OptimiHealth #LifeSciences
Optimi retweeted
Sounding the alarm - if MDMA & psilocybin are approved by FDA, most MDMA & psilocybin could still be scheduled I, wildly inconsistent with the science. @Ravarora1 & I lay out the case for why we need to avoid a "bifurcated schedule" that only reschedules the commercial FDA approved product. Please repost & spread the word! illusionconsensus.com/p/psyc…
Reminder: Optimi Health will present a corporate overview at the ThinkEquity Conference on October 15, at 4:00 p.m. ET, at the Mandarin Oriental Hotel in New York City. For more information and to register for the conference, visit: bit.ly/4hK19sx $OPTH
Optimi retweeted
There hasn’t been anything new developed in the past 4 decades to treat mental health issues from anxiety to OCD to depression to bipolar disorder. Finally there is something new that is proven to help. Hope the USA takes the lead here and now and gets these drugs developed.
Psychedelic medicine is approaching a turning point.
In a new Fortune commentary, Optimi Health CEO and Co-Founder Dane Stevens explains why the U.S. needs the right infrastructure to support regulated access.
Read more: fortune.com/2026/10/12/psych…
